Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations

References

• Fiore AE, Shay DK, Broder K et al.; Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR58, 1–52 (2009).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Influenza vaccination coverage among children and adults – United States, 2008–09 influenza season. MMWR58, 1091–1095 (2009).
   PubMedGoogle Scholar
• Gasparini R, Laghi-Pasini F, Staniscia T et al. A. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One4(2), e4384 (2009).
   PubMedGoogle Scholar
• Walker WT, Oeser C, Reiner A et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. Br. Med. J.340, c2649 (2010).
   PubMedGoogle Scholar
• Baras B, Bouveret N, Devaster JM et al. A vaccine manufacturer’s approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respi. Viruses2(6), 251–260 (2008).
   PubMed Web of Science ®Google Scholar
• Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations. Am. J. Trop. Med. Hyg.68(3), 341–344 (2003).
   PubMed Web of Science ®Google Scholar
• Breau L, McGrath PJ, Craig K, Santor D, Cassidy KL, Reid G. Facial expression of children receiving immunizations: a principal components analysis of the child facial coding system. Clin. J. Pain17(2), 178–186 (2001).
   PubMed Web of Science ®Google Scholar
• Sendi P, Locher R, Bucheli B et al. Intranasal influenza vaccine in a working population. Clin. Infect. Dis.38(7), 974–980 (2004).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Thomas DN, Poffenberger KL et al. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch. Vaccine27(Suppl. 6), 60–66 (2009).
   Google Scholar
• Tamura S. Studies on the usefulness of intranasal inactivated influenza vaccines. Vaccine28(38), 6393–6397 (2010).
   PubMed Web of Science ®Google Scholar
• Song JH, Nguyen HH, Cuburu N et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl Acad. Sci. USA105(5), 1644–1649 (2008).
   PubMed Web of Science ®Google Scholar
• Prabakaran M, Madhan S, Prabhu N, Geng GY, New R, Kwang J. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. Antiviral Res.86(2), 180–187 (2010).
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi. Viruses2(6), 193–202 (2008).
   PubMed Web of Science ®Google Scholar
• Waldman RH, Bond JO, Levitt LP et al. An evaluation of influenza immunization. influence of route of administration and vaccine strain. Bull. World Health Organ.41(3), 543–548 (1969).
   PubMed Web of Science ®Google Scholar
• Liem KS, Jacobs J, Marcus EA, van Strik R. The protective effect of intranasal immunization with inactivated influenza virus vaccine. Postgrad. Med. J.49(569), 175–179 (1973).
   PubMed Web of Science ®Google Scholar
• Lycke N, Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology59(2), 301–308 (1986).
   PubMed Web of Science ®Google Scholar
• Sixma TK, Kalk KH, van Zanten BA et al. Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin. J. Mol. Biol.230(3), 890–918 (1993).
   PubMed Web of Science ®Google Scholar
• Glück U, Gebbers JO, Glück R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol.73(9), 7780–7786 (1999).
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350(9), 896–903 (2004).
   PubMed Web of Science ®Google Scholar
• van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol.165(9), 4778–4782 (2000).
   PubMed Web of Science ®Google Scholar
• Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine18(22), 2416–2425 (2000).
   PubMed Web of Science ®Google Scholar
• Xiaowen Z, Qinghua Y, Xiaofei Z, Qian Y. Co-administration of inactivated avian influenza virus with CpG or rIL-2 strongly enhances the local immune response after intranasal immunization in chicken. Vaccine27(41), 5628–5632 (2009).
   PubMed Web of Science ®Google Scholar
• Hu KF, Lövgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug Deliv. Rev.51(1–3), 149–159 (2001).
   PubMed Web of Science ®Google Scholar
• Boyce TG, Hsu HH, Sannella EC et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine19(2–3), 217–226 (2000).
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Watanabe I, Ito S et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol.79(5), 2910–2919 (2005).
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I, Fisher A, Illum L et al. Effective nasal influenza vaccine delivery using chitosan. Vaccine23(35), 4367–4374 (2005).
   PubMed Web of Science ®Google Scholar
• Kiyono H, Fukuyama S. NALT-versus Peyer’s-patch-mediated mucosal immunity. Nat. Rev. Immunol.4(9), 699–710 (2004).
   PubMed Web of Science ®Google Scholar
• Renegar KB, Small PA Jr, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol.173(3), 1978–1986 (2004).
   PubMed Web of Science ®Google Scholar
• Mazanec MB, Lamm ME, Lyn D, Portner A, Nedrud JG. Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract. Virus Res.23(1–2), 1–12 (1992).
   PubMed Web of Science ®Google Scholar
• Renegar KB, Jackson GD, Mestecky J. In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA. J. Immunol.160(3), 1219–1223 (1998).
   PubMed Web of Science ®Google Scholar
• Liew FY, Russell SM, Appleyard G, Brand CM, Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur. J. Immunol.14(4), 350–356 (1984).
   PubMed Web of Science ®Google Scholar
• Tamura SI, Asanuma H, Ito Y et al. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur. J. Immunol.22(2), 477–481 (1992).
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Kawaguchi A, Tamura SI et al. Intranasal immunization with H5N1 vaccine plus poly I:poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect.9(11), 1333–1340 (2007).
   PubMed Web of Science ®Google Scholar
• Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol.75(11), 5141–5150 (2001).
   PubMed Web of Science ®Google Scholar
• Mendelman PM, Rappaport R, Cho I et al. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr. Infect. Dis. J.23(11), 1053–1055 (2004).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr.136(2), 168–175 (2000).
   PubMed Web of Science ®Google Scholar
• Asahi Y, Yoshikawa T, Watanabe I et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J. Immunol.168(6), 2930–2938 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor HP, Dimmock NJ. Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J. Exp. Med.161(1), 198–209 (1985).
   PubMed Web of Science ®Google Scholar
• Lowell GH, Smith LF, Seid RC, Zollinger WD. Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. J. Exp. Med.167(2), 658–663 (1988).
   PubMed Web of Science ®Google Scholar
• Wetzler LM. Immunopotentiating ability of neisserial major outer membrane proteins. Use as an adjuvant for poorly immunogenic substances and potential use in vaccines. Ann. NY Acad. Sci.15(730), 367–370 (1994).
   Google Scholar
• VanCott TC, Kaminski RW, Mascola JR et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J. Immunol.160(4), 2000–2012 (1998).
   PubMed Web of Science ®Google Scholar
• Cyr SL, Jones T, Stoica-Popescu I et al. Intranasal proteosome™-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Vaccine25(29), 5378–5389 (2007).
   PubMed Web of Science ®Google Scholar
• Batzloff MR, Yan H, Davies MR et al. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. J. Infect. Dis.192(8), 1450–1455 (2005).
   PubMed Web of Science ®Google Scholar
• Mallett CP, Hale TL, Kaminski RW et al. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect. Immun.63(6), 2382–2386 (1995).
   PubMed Web of Science ®Google Scholar
• Jones T, Cyr S, Allard F, Bellerose N, Lowell GH, Burt DS. Protollin™: a novel adjuvant for intranasal vaccines. Vaccine22(27–28), 3691–3697 (2004).
   PubMed Web of Science ®Google Scholar
• Langley JM, Halperin SA, McNeil S et al. Safety and immunogenicity of a Proteosome™-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine24(10), 1601–1608 (2006).
   PubMed Web of Science ®Google Scholar
• Pasetti MF, Resendiz-Albor A, Ramirez K et al. Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques. Clin. Pharmacol. Ther.82(6), 672–685 (2007).
   PubMed Web of Science ®Google Scholar
• Hu MC, Jones T, Kenney RT, Barnard DL, Burt DS, Lowell GH. Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice. Vaccine25(34), 6334–6340 (2007).
   PubMed Web of Science ®Google Scholar
• Lynch EC, Blake MS, Gotschlich EC, Mauro A. Studies of porins: spontaneously transferred from whole cells and reconstituted from purified proteins of Neisseria gonorrhoeae and Neisseria meningitidis. Biophys. J.45(1), 104–107 (1984).
   PubMed Web of Science ®Google Scholar
• Massari P, Henneke P, Ho Y, Latz E, Golenbock DT, Wetzler LM. Cutting edge: immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent. J. Immunol.168(4), 1533–1537 (2002).
   PubMed Web of Science ®Google Scholar
• Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem.274(16), 10689–10692 (1999).
   PubMed Web of Science ®Google Scholar
• Faure E, Thomas L, Xu H, Medvedev A, Equils O, Arditi M. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J. Immunol.166(3), 2018–2024 (2001).
   PubMed Web of Science ®Google Scholar
• Chabot SM, Chernin TS, Shawi M et al. TLR-2 activation by proteosomes promotes uptake of particulate vaccines at mucosal surfaces. Vaccine25(29), 5348–5358 (2007).
   PubMed Web of Science ®Google Scholar
• Levi R, Aboud-Pirak E, Leclerc C, Lowell GH, Arnon R. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Vaccine13(14), 1353–1359 (1995).
   PubMed Web of Science ®Google Scholar
• Plante M, Jones T, Allard F et al. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine20(1–2), 218–225 (2001).
   PubMed Web of Science ®Google Scholar
• Jones T, Allard F, Cyr SL et al. A nasal Proteosome™ influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. Vaccine21(25–26), 3706–3712 (2003).
   PubMed Web of Science ®Google Scholar
• Lowell GL, Burt D, White G, Fries L. Proteosome technology for vaccines and adjuvants. In: New Generation Vaccines. Levine M (Ed.). Marcel Decker Inc., NY, USA, 271–282 (2004).
   Google Scholar
• Reuman PD, Keely S, Schiff GM. Assessment of signs of influenza illness in the ferret model. J. Virol. Methods24(1–2), 27–34 (1989).
   PubMed Web of Science ®Google Scholar
• Frenkel D, Puckett L, Petrovic S et al. A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. Ann. Neurol.63(5), 591–601 (2008).
   PubMed Web of Science ®Google Scholar
• Treanor J, Nolan C, O’Brien D et al. Intranasal administration of a proteosome–influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine24(3), 254–262 (2006).
   PubMed Web of Science ®Google Scholar
• Fries L, Lambkin R, Gelder C et al. FluInsure™, an inactivated trivalent influenza vaccine for intranasal administration, is protective in human challenge with A/Panama/2007/99 (H3N2) virus. Presented at: International Conference on Options for the Control of Influenza V. Okinawa, Japan, 7–11 October 2003.
   Google Scholar
• Langley JM, Akoi F, Ward BJ et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine29(10), 1921–1928 (2011).
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi. Viruses.2(6), 193–202 (2008).
   PubMed Web of Science ®Google Scholar
• Herrera GA, Iwane MK, Cortese M et al. Influenza vaccine effectiveness among 50–64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003–2004. Vaccine25(1), 154–160 (2007).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N. Engl. J. Med.338(20), 1405–1412 (1998).
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I. Nasal vaccine innovation. J. Drug Targeting18(10), 771–786 (2010).
   PubMed Web of Science ®Google Scholar
• FluMist™, Influenza Vaccine Live, Intranasal. Prescribing Information. MedImmune, Gaithersburg, MD, USA (2007).
   Google Scholar
• Rhorer J, Ambrose CS, Dickinson S et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine27(7), 1101–1110 (2009).
   PubMed Web of Science ®Google Scholar
• Govaert TM, Thijs CT, Masurel N et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA272, 1661–1665 (1997).
   Google Scholar
• Ruben FL. Prevention and control of influenza. Role of vaccine. Am. J. Med.82(6A), 31–34 (1987).
   PubMed Web of Science ®Google Scholar
• Johnson PR, Feldman S, Thompson JM, Mahoney JD, Wright PF. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J. Infect. Dis.154(1), 121–127 (1986).
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med.309(1), 13–17 (1983).
   PubMed Web of Science ®Google Scholar
• Forrest BD, Pride MW, Dunning AJ et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin. Vaccine Immunol.15(7), 1042–1053 (2008).
   PubMed Web of Science ®Google Scholar
• Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun.69(7), 4545–4553 (2001).
   PubMed Web of Science ®Google Scholar